Missed opportunities to identify cryptococcosis in COVID-19 patients: a case report and literature review
| Autor: | Daniel B. Chastain, Andrés F. Henao-Martínez, Austin C. Dykes, Gregory M. Steele, Laura Leigh Stoudenmire, Geren M. Thomas, Vanessa Kung, Carlos Franco-Paredes |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Infectious Disease, Vol 9 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2049-937X 20499361 |
| DOI: | 10.1177/20499361211066363 |
| Popis: | SARS-CoV-2 may activate both innate and adaptive immune responses ultimately leading to a dysregulated immune response prompting the use of immunomodulatory therapy. Although viral pneumonia increases the risk of invasive fungal infections, it remains unclear whether SARS-CoV-2 infection, immunomodulatory therapy, or a combination of both are responsible for the increased recognition of opportunistic infections in COVID-19 patients. Cases of cryptococcosis have previously been reported following treatment with corticosteroids, interleukin (IL)-6 inhibitors, and Janus kinase (JAK) inhibitors, for patients with autoimmune diseases, but their effect on the immunologic response in patients with COVID-19 remains unknown. Herein, we present the case of a patient with COVID-19 who received high-dose corticosteroids and was later found to have cryptococcosis despite no traditional risk factors. As our case and previous cases of cryptococcosis in patients with COVID-19 demonstrate, clinicians must be suspicious of cryptococcosis in COVID-19 patients who clinically deteriorate following treatment with immunomodulatory therapies. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|